BTAI

BioXcel Therapeutics Inc

Add to Watchlist

Advanced Chart

4.839

+0.799(19.777%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.850

Open

4.320

VWAP

4.60

Vol

4.32M

Mkt Cap

24.47M

Low

4.040

Amount

19.88M

EV/EBITDA(TTM)

Total Shares

37.53M

98.98M

EV/OCF(TTM)

P/S(TTM)

6.84

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

212.50K

-80.75%

257.50K

+20.33%

352.50K

-3.69%

Estimates Revision

The market is revising Downward the revenue expectations for BioXcel Therapeutics, Inc. (BTAI) for FY2025, with the revenue forecasts being adjusted by -57.91% over the past three months. During the same period, the stock price has changed by 226.97%.

Revenue Estimates for FY2025

Revise Downward

-57.91%

In Past 3 Month

Stock Price

Go Up

+226.97%

In Past 3 Month

4 Analyst Rating

3.32% Upside

Wall Street analysts forecast BTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTAI is 5.00 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

1 Sell

Hold

3.32% Upside

Current: 4.839

Low

2.00

Averages

5.00

High

8.00

3.32% Upside

Current: 4.839

Low

2.00

Averages

5.00

High

8.00

Lucid Capital

Buy

maintain

$15

2025-07-15

Reason

Lucid Capital

Price Target

$15

2025-07-15

maintain

Buy

Reason

Lucid Capital reiterates a Buy rating on BioXcel Therapeutics with a $15 price target after the company announced that the U.S. Patent and Trademark Office approved its patent application which covers the use of a single dose of dexmedetomidine in an oromucosal formulation for treating acute agitation in schizophrenia or bipolar patients with QT prolongation under six microseconds. Once officially granted, the patent will be eligible for inclusion in the FDA's Orange Book as the 14th listed patent for Igalmi and is expected to expire on January 12, 2043, pending any patent term adjustments, the analyst tells investors in a research note.

Lucid Capital

NULL

Buy

initiated

$66

2025-06-25

Reason

Lucid Capital

Price Target

$66

2025-06-25

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of BioXcel Therapeutics with a Buy rating and $66 price target. BioXCel is expanding the use of its approved agitation drug, Igalmi, for at-home use and for Alzheimer's disease, the analyst tells investors in a research note. The firm says there are 7M patients diagnosed with Alzheimer's disease in the U.S. alone and the numbers are expected to double every 20 years with the aging population. It sees blockbuster potential for Igalmi.

H.C. Wainwright

maintain

$3 -> $8

2025-06-23

Reason

H.C. Wainwright

Price Target

$3 -> $8

2025-06-23

maintain

Reason

H.C. Wainwright raised the firm's price target on BioXcel Therapeutics to $8 from $3 and keeps a Buy rating on the shares. The firm cites After the dilution associated with the most recent equity financing in March as well as the impact of the reverse stock split implemented in February for the new target.

Rodman & Renshaw

Elemer Piros

Strong Buy

Initiates

$65

2025-03-19

Reason

Rodman & Renshaw

Elemer Piros

Price Target

$65

2025-03-19

Initiates

Strong Buy

Reason

Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a Buy rating and $65 price target. The firm sees e blockbuster potential and over 2,900% share upside with BioXCel expanding the use of its approved drug, Igalmi, for at-home use and for Alzheimer's disease. The convenience of using the drug at home grows the potential by tenfold, with a market potential of $2B in the U.S., the firm tells investors in a research note.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$5 → $3

2025-01-30

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$5 → $3

2025-01-30

Maintains

Strong Buy

Reason

B of A Securities

Geoff Meacham

Strong Buy

Sell

Downgrades

$7 → $0.25

2025-01-07

Reason

B of A Securities

Geoff Meacham

Price Target

$7 → $0.25

2025-01-07

Downgrades

Strong Buy

Sell

Reason

BofA analyst Alec Stranahan downgraded BioXcel Therapeutics to Underperform from Buy with a price target of 25c, down from $7. The firm cites an "uncertain" agitation market opportunity, "lingering regulatory overhangs," and BioXcel's thinning cash position. More broadly for the sector, while political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as "markedly improved from 2022 lows."

See All Ratings

Valuation Metrics

The current forward P/E ratio for BioXcel Therapeutics Inc (BTAI.O) is -0.82, compared to its 5-year average forward P/E of -3.73. For a more detailed relative valuation and DCF analysis to assess BioXcel Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.73

Current PE

-0.82

Overvalued PE

0.21

Undervalued PE

-7.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.09

Current EV/EBITDA

-2.02

Overvalued EV/EBITDA

-0.17

Undervalued EV/EBITDA

-6.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

69.46

Current PS

20.01

Overvalued PS

197.66

Undervalued PS

-58.75

Financials

Annual

Quarterly

FY2025Q1

YoY :

-71.13%

168.00K

Total Revenue

FY2025Q1

YoY :

-58.20%

-10.10M

Operating Profit

FY2025Q1

YoY :

-72.92%

-7.25M

Net Income after Tax

FY2025Q1

YoY :

-89.20%

-1.50

EPS - Diluted

FY2025Q1

-12.04M

Free Cash Flow

FY2025Q1

YoY :

+6.28%

91.67

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

YoY :

-6.20%

-4.32K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

1.7K

USD

0-12

Months

20.5K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

1.7K

USD

0-12

Months

20.5K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BTAI News & Events

Events Timeline

2025-08-06 (ET)

2025-08-06

07:25:09

BioXcel Therapeutics announces publication on active ingredient in BXCL-501

2025-08-01 (ET)

2025-08-01

07:02:03

BioXcel announces last patient visit in SERENITY at-home Phase 3 trial

2025-07-21 (ET)

2025-07-21

07:04:33

BioXcel Therapeutics submits pre-supplemental NDA meeting package for IGALMI

News

2.0

08-05TipRanks

3 Penny Stocks to Watch Now, 8/5/25

9.0

08-01Newsfilter

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

9.0

07-01NASDAQ.COM

Why BioXcel Therapeutics Is Rising In Pre-market?